A Longitudinal Study on Family Adaptation and Relationship Dynamics in Pediatric Rare Diseases

ConditionRare Diseases
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age1-18
SponsorMarkus A. Landolt

About this trial

Rare diseases in children can affect not only the child's health but also the well-being and relationships within the entire family. Parents often experience stress, uncertainty, and emotional strain, which may in turn influence their child's mental health and quality of life. However, little is known about how families adapt over time to living with a rare disease or how daily experiences and family interactions shape this process.

This study aims to better understand how children with rare diseases and their caregivers adjust psychologically and emotionally over time. It will examine how factors such as parental stress, uncertainty, coping strategies, and family communication are linked to the mental health and quality of life of both children and parents.

The study will include children and adolescents (ages 1-18) with a diagnosed rare disease and their caregivers. Participants will complete online questionnaires at four time points over one year. A subgroup of families will also take part in a two-week smartphone-based assessment, where parents report their daily experiences, such as stress, emotions, and worries, several times per day. Some children and adolescents will additionally participate in interviews to share their own perspectives.

The main outcomes of interest are the child's mental health and quality of life. The study will also assess parental well-being and family functioning to understand how these factors influence each other over time.

By combining long-term and daily data, this study will provide a detailed picture of how families cope with rare diseases in everyday life. The findings may help improve psychological support and guide the development of targeted interventions for families affected by rare pediatric conditions.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diagnosed with an RD listed in Table 2.

Age between 8 and 18 years.

Sufficient knowledge of the German language.

Declaration of informed consent must be signed by at least one legal guardian for all participants under 18; adolescents aged 14 - 17 additionally provide their own written consent.

Disqualifiers

The child is affected by an RD other than listed in Table 2.

Age under 8 or over 18 years.

Not sufficient knowledge of the German language.

Lack of informed consent from at least one legal guardian (required for all participants under 18); and, for adolescents aged 14 - 17, absence of adolescent's own written consent.

Trial population

The study population consists of families (children/adolescents and their caregivers) affected by a pediatric rare disease. Participants are recruited through two primary sources: * Clinical Source: Patients and their families are identified and recruited through supervising physicians at the University Children's Hospital Zurich, Switzerland. * Community Source: Families are also reached via patient organizations dedicated to rare diseases, using their mailing lists and communication channels. The population includes children and adolescents across various functional statuses (primarily somatic vs. primarily cognitive limitations) to capture a broad spectrum of family adaptation processes. Recruitment is focused on German-speaking families (with English as an additional option for caregivers) who reside at home, ensuring that the collected data reflects daily family life and relationship dynamics in a natural setting.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Child Mental Health and Health-Related Quality of Life

The primary endpoints of this study are the mental health and health-related quality of life (HRQoL) of the children and adolescents affected by an RD. Mental health includes internalizing and externalizing symptoms, as well as general psychological well-being. HRQoL encompasses subjective evaluations of physical, emotional, and social functioning, as well as the perceived impact of health conditions on daily life and overall well-being

Time frame
Baseline, 3 months, 6 months, and 12 months

Secondary outcomes

1

Parental and family-level factors

These include parental psychological well-being (e.g., depression, anxiety, stress, HRQoL), intolerance of uncertainty, worrying, communication patterns, daily coping, illness appraisal, parenting, and family functioning - assessed through longitudinal and ESM data.

Time frame
Baseline, 3 months, 6 months, 12 months, 24 months, 36 months, and 48 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Markus A. Landolt

Lead sponsor

University Children's Hospital, Zurich

Sponsor institution

This trial is not recruiting at the moment. You can still explore other options: